Abridge Stock IPO: $5.3B AI Scribe Outlook & Guide
This page contains links to our partners. We may be compensated when a link is clicked. Read the disclosures to learn more.
Explore opportunities to invest in Abridge stock before the IPO. Invest leading AI, fintech, and defense startups at Fundrise Venture ($10 minimum investment).
Snapshot
- Company Status: Private, Series E – June 2025
- Focus: Healthcare AI Transcription
- IPO Timeline: 2-5 Years (Est.)
- Retail Access: Limited, via Platforms and Syndication
Table of Contents
Notable Abridge News
06/24/2025: Abridge Secures $300M Series E
02/17/2025: Abridge Announces $250M Series D
02/24/2024: Abridge Raises $150M Series C
10/26/2023: Abridge Raises $30M Series B
Older News…
About Abridge
Abridge is an AI-powered healthcare software company that transforms patient-clinician conversations into structured clinical notes.
It was founded in 2018 by Dr. Shiv Rao, a cardiologist who saw firsthand how much time doctors spent on paperwork. The idea originated from his and his colleagues’ work at UPMC and Carnegie Mellon University in Pittsburgh.
From early days using sanitized clinical encounter data, the company built a proprietary dataset of millions of medical conversations to train its NLP models.
Abridge’s primary business lines include an AI “scribe” platform that transcribes and summarizes patient-doctor conversations in real time, and then integrates those summaries into electronic health records (EHRs) for clinicians — dramatically reducing documentation burden.
Its headquarters is in Pittsburgh, Pennsylvania. The name “Abridge” evokes the idea of condensing — or “abridging” — long, complex conversations into concise, usable clinical summaries.
Abridge is regarded as a leader among AI-medical-scribe firms, often cited as ahead of incumbents thanks to its deep clinical specialization, multilingual support, and “Linked Evidence” feature that links summaries back to the source conversation.
With substantial venture capital funding and large healthcare providers as clients, Abridge aims to expand into broader market verticals and further integration within U.S. healthcare networks.
Ownership
Abridge is a venture-backed startup owned by its founders, employees, and multiple venture capital firms.
Prominent venture capital investors include Andreessen Horowitz, Khosla Ventures, Elad Gill, WndrCo, IVP, Bessemer, CVS Health Ventures, California Health Care Foundation, CapitalG, K. Ventures, Lightspeed, NVentures, SV Angel, Spark Capital, Kaiser Permanente Ventures, Aetna Ventures, Mass General Brigham, Union Square Ventures, Wittington Ventures. American College of Cardiology Foundation, LifePoint Health, SCAN Group, UPMC Enterprises, KdT Ventures, and Pillar VC.
Abridge Funding Rounds
| Round | Date | Est. Valuation | Raise Amount | Price |
|---|---|---|---|---|
| Series E | 06/23/25 | $5.3B | $300.0M | $158.48 |
| Series D | 02/16/25 | $2.8B | $250.0M | $90.01 |
| Series C | 02/21/24 | NA | $150.0M | $33.13 |
| Series B | 10/25/23 | NA | $30.0M | $10.97 |
| Series A Extension | 08/10/22 | NA | $12.5M | $8.82 |
| Series A | 10/05/20 | NA | $15.0M | $4.77 |
| Source: Caplight |
Valuation
The latest confirmed Abridge valuation is $5.3 billion based on the Series E funding round announced in June 2025.
Secondary marketplace data from Hiive and Caplight suggest the valuation has surpassed $8 billion as of Q4 2025.
IPO Potential
The Abridge IPO date is unknown and likely a few years away.
The company is relatively young, having raised its Series A in 2020 and riding the post-ChatGPT AI euphoria.
Having raised significant capital from top-tier venture capital firms, it will eventually need to find an exit. But a majority of its capital was raised in 2025, giving it a few years’ runways before it needs to provide widespread liquidity to investors.
If it chooses a public route, it could be a banner IPO for the city of Pittsburgh. As an acquisition candidate, several healthcare conglomerates or software providers may be interested, some of which have already invested pre-IPO.
An S-1 filing (confidential or public) is the most accurate sign that an IPO may be forthcoming. The intent to move forward with an IPO is usually leaked to the press long before the S-1 filing becomes available to the public.
How to Invest in Abridge Stock
At this stage of growth, pre-IPO shares may become available on various platforms.
However, I have not seen widespread availability of investment opportunities. This may indicate either a tight restriction on selling shares pre-IPO, sufficient liquidity through internal share sales, or employee desire to hold shares for the long term.
Retail investors can follow the items below to increase their chances of investing in Abridge stock before, during, and after the IPO.
1. Invest in Abridge pre-IPO
Pre-IPO investment platforms and syndicators may offer Abridge stock for purchase as employees or early investors seek to sell some of their shares before the Abridge IPO.
Accredited investors may access shares, provided they are registered on the platform and receive notifications about their availability.
Monitor pre-IPO investing platforms such as Hiive, Equitybee, Forge Global, and EquityZen for share availability.
If shares become available, expect to pay at least a $10,000 investment minimum, often more.
Non-accredited investors can invest in pre-IPO companies via venture capital funds targeted at retail investors.
Fundrise Venture (review) is a premium option and affordable for most investors ($10 minimum). However, Abridge is not currently in the portfolio.
Please note: This is a testimonial in partnership with Fundrise. We earn a commission from partner links on AccessIPOs.com. All opinions are my own.
2. Participate in the Abridge IPO through a broker
When a company eventually goes public, retail investors can often buy the stock during the IPO at the IPO price.
In the past, only Wall Street’s top customers could invest in IPOs. But the trend is moving toward providing more IPO access to retail investors through participating discount brokers.
Some online brokers (like the ones listed below) allow investors to invest in IPOs for free, even if they have limited funds in their accounts.
TradeStation has a more established track record of accessing more than 400 IPOs and secondary offerings via its partnership with Click Markets.
Robinhood has the advantage of Silicon Valley networks and a history of getting allocations for high-profile IPOs.
Check out this list of the best brokers for IPO investing to learn more about IPO access for retail investors.
3. Buy Abridge stock after the IPO
Most investors must wait until after a company’s IPO to buy shares.
Waiting allows you to access more established financial data after the first quarter of public trading, compared to the limited financials available pre-IPO.
High-demand IPOs sometimes see initial exaggerated valuations. While this offers a chance to sell near the peak, prices frequently revert to fairer valuations later.
Expect stock prices to drop after the first and second-quarter earnings reports reveal significant numbers.
These post-earnings dips can be great entry points. Avoid buying immediately after the IPO to steer clear of lockup expirations and initial overvaluation.
However, the most disruptive companies often deliver the best returns over a decade, so patience is key.
Investor Takeaways
Abridge’s rapid growth acceleration shows how deeply specialized healthcare AI companies can scale when they solve a costly problem for clinicians.
Its surging valuation reflects strong institutional conviction and that future investors should weigh expectations for long-term revenue against the current enthusiasm surrounding medical AI.
The company’s deep ties to major health systems through strategic investment suggest an uncommon level of clinical validation, which may give it durability once the AI funding cycle cools.
Limited secondary-market availability indicates that insiders are confident in the company’s future or are bound by tight controls, both of which can affect how retail investors gain exposure before an eventual IPO.
The funding timeline suggests Abridge has a runway before facing liquidity pressure, meaning the path to a public listing will depend more on market conditions than on capital necessity.
For now, Abridge stands out as a rare private-market healthcare AI firm with both scale and clinical credibility, making it a company worth tracking closely while the IPO window is open.
Investors interested in Abridge stock or the IPO can monitor this page for the latest.
Abridge News Archive
08/11/2022: Abridge Secures $12.5M in Funding
Frequently Asked Questions (FAQs)
Craig Stephens founded Access IPOs in 2016 to help ordinary investors explore IPO and pre-IPO opportunities. He also manages the Access Club, a membership community for IPO and startup investors. Craig studied Finance at Michigan State University and lives in Northern Virginia. Learn more about Craig.
* This is a testimonial in partnership with Fundrise, Hiive, Robinhood, and other affiliate partners. We earn a commission from partner links on AccessIPOs.com. All opinions are my own. If you sign up with one of our partners through certain on this website, Access IPOs will be compensated at no additional cost to the reader. See the full disclosure here. Risk Statement: Access IPOs is for informational purposes only and does not recommend buying or selling any specific pre-IPO company, IPO, or public company. Investing in IPOs and pre-IPO startups involves significant risk. Do not invest in companies based solely on what is included in this article. Only invest in IPOs and pre-IPO companies with money you can afford to lose. Mentions of specific investments should not be construed as financial advice. Conduct personalized research and consider consulting with an investment advisor before investing. Disclosure: The author may hold an active or pending position in this company either directly or indirectly through an investment fund.
